Description

NP213 TFA is a rapidly acting, novel, first-in-class synthetic antimicrobial peptide (AMP), has anti-fungal activities. NP213 TFA targets the fungal cytoplasmic membrane and plays it role via membrane perturbation and disruption. NP213 TFA is effective and well-tolerated in resolving nail fungal infections[1][2].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)–COVID-19-immunoregulation–C44H85F3N28O9—-[1]Mercer DK,et al. Improved Methods for Assessing Therapeutic Potential of Antifungal Agents against Dermatophytes and Their Application in the Development of NP213, a Novel Onychomycosis Therapy Candidate.Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e02117-18.|[2]Neelabh, et al. Sequential and Structural Aspects of Antifungal Peptides from Animals, Bacteria and Fungi Based on Bioinformatics Tools.Probiotics Antimicrob Proteins. 2016 Jun;8(2):85-101.|[3]Novamycin®/NP339 Technology Summary—-1207.32–99.80–N=C(N)NCCC[C@H](NC([C@@H](NC([C@@H](NC([C@@H](N1)CCCNC(N)=N)=O)CCCNC(N)=N)=O)CCCNC(N)=N)=O)C(N[C@H](C(N[C@H](C(N[C@H](C1=O)CCCNC(N)=N)=O)CCCNC(N)=N)=O)CCCNC(N)=N)=O.O=C(O)C(F)(F)F–Infection–DMSO : 100 mg/mL (ultrasonic)|H2O : 100 mg/mL (ultrasonic)–Fungal—-Anti-infection–Peptides